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Abstract
Background: Japanese encephalitis virus (JEV), a member of the Flaviviridae family, causes around 68,000 encephalitis cases
annually, of which 20–30% are fatal, while 30–50% of the recovered cases develop severe neurological sequelae. Specific
antivirals for JEV would be of great importance, particularly in those cases where the infection has become persistent. Being
indispensable for flaviviral replication, the NS2B-NS3 protease is a promising target for design of anti-flaviviral inhibitors.
Contrary to related flaviviral proteases, the JEV NS2B-NS3 protease is structurally and mechanistically much less
characterized. Here we aimed at establishing a straightforward procedure for cloning, expression, purification and
biochemical characterization of JEV NS2B(H)-NS3pro protease.
Methodology/Principal Findings: The full-length sequence of JEV NS2B-NS3 genotype III strain JaOArS 982 was obtained as
a synthetic gene. The sequence of NS2B(H)-NS3pro was generated by splicing by overlap extension PCR (SOE-PCR) and
cloned into the pTrcHisA vector. Hexahistidine-tagged NS2B(H)-NS3pro, expressed in E. coli as soluble protein, was purified
to .95% purity by a single-step immobilized metal affinity chromatography. SDS-PAGE and immunoblotting of the purified
enzyme demonstrated NS2B(H)-NS3pro precursor and its autocleavage products, NS3pro and NS2B(H), as 36, 21, and
10 kDa bands, respectively. Kinetic parameters, Km and kcat, for fluorogenic protease model substrates, Boc-GRR-amc, Boc-
LRR-amc, Ac-nKRR-amc, Bz-nKRR-amc, Pyr-RTKR-amc and Abz-(R)4SAG-nY-amide, were obtained using inner filter effect
correction. The highest catalytic efficiency kcat/Km was found for Pyr-RTKR-amc (kcat/Km: 1962.96685.0 M
21 s
21) and the
lowest for Boc-LRR-amc (kcat/Km: 3.7460.3 M
21 s
21). JEV NS3pro is inhibited by aprotinin but to a lesser extent than DEN
and WNV NS3pro.
Conclusions/Significance: A simplified procedure for the cloning, overexpression and purification of the NS2B(H)-NS3pro
was established which is generally applicable to other flaviviral proteases. Kinetic parameters obtained for a number of
model substrates and inhibitors, are useful for the characterization of substrate specificity and eventually for the design of
high-throughput assays aimed at antiviral inhibitor discovery.
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Introduction
Japanese encephalitis virus (JEV) is a mosquito borne flavivirus
that causes severe central nervous system diseases such as an acute
flaccid paralysis, aseptic meningitis and encephalitis [1]. It belongs
to the genus Flavivirus (family Flaviviridae) which comprises over 70
viruses many of which are human pathogens, including West Nile
virus (WNV), Dengue virus (DEN), Yellow fever virus (YFV),
Murray Valley Encephalitis Virus (MVEV), Kunjin Virus
(KUNV) and Tick-Borne Encephalitis Virus (TBEV) [2]. Japanese
encephalitis (JE) is among the most important viral encephalitides
in Asia [3–5]. Moreover, the disease is not restricted to Asia and
cases also occur sporadically in northern Australia and western
Pacific [6]. Of about 68,000 estimated annual cases, approxi-
mately 20–30% are fatal, and 30–50% of survivors have significant
neurologic sequelae [7,8]. Since the zoonosis is endemic in large
parts of Asia, it is not likely to ever be extinguished.
Currently there is no antiviral therapy for JEV or any other
flaviviral infection, and so far the main strategy to control the
incidence is by preventive methods such as vaccination and
preventing mosquito bites [9–11]. Although the improvements in
JEV vaccination coverage has reduced the JE incidence, about
55,000 (81%) out of the total annual cases still occur in areas with
well established or developing JE vaccination programs [12].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36872Effective antiviral therapy is thus urgently needed, especially for
those cases where the infection has become persistent. One
approach to develop anti-JEV therapy is to interfere with the life
cycle of the virus, and exploit the molecular targets such as
envelope glycoprotein, NS3 protease, NS3 helicase, NS5 methyl-
transferase and NS5 RNA- dependent RNA polymerase [13].
Unlike several other flaviviruses such as DEN, WNV and MVEV
[14–16] whose protease enzymes are extensively characterised as
potential drug targets, the JEV protease is comparatively less
studied with a view to structure-activity relations.
The JEV two-component protease NS2B/NS3 is responsible for
processing the viral polyprotein precursor to the mature viral
proteins involved in viral pathogenesis, and therefore considered
an important drug target in JEV [17,18]. The N-terminal one-
third (180 residues) of NS3 represents the protease domain
NS3(pro) that works in coordination with the C-terminal two-third
portion RNA helicase during viral propagation [19,20]. The
proteolytic domain contains a classical catalytic triad of H51, D75
and S135, and autocatalytic proteolytic cleavage at the NS2B/
NS3 polyprotein junction leads to the formation of a non-covalent
complex of NS2B and NS3 [21]. Earlier studies have revealed that
a 35–48 amino acid residues long central hydrophilic region
NS2B(H) of NS2B interacts directly with the NS3(pro) and
promotes folding of NS3(pro) into a catalytically competent
conformation [22–25].
Currently, there is no X-ray crystallographic structure available
for the JEV protease, but crystal structures of the similar proteases
from DEN and WNV have provided insight into the mechanism of
cofactor-dependent activation and revealed an ‘induced fit’
mechanism of catalysis [26,27]. By analysis of chimeric viral
proteases of DEN2 and YFV, it was shown that the YFV
polyprotein cleavage sites were efficiently cleaved by the chimeric
protease containing the YFV or DEN2 NS3 protease domain,
while the DEN2 polyprotein sites were not cleaved by the YFV
chimeric protease containing YFV NS3(pro), suggesting that
cleavage requires specific local interactions between substrates
and the binding pocket site of the enzyme [28]. The substrate
recognition sequence is highly conserved in all flaviviruses and
consists of two basic residues in P2 and P1 followed by a small
unbranched amino acid in P1’ [22,43]. Substrate profiling studies
found that the WNV protease was highly selective for the cleavage
site sequence motif (K/R)QGG, whereas DEN protease also
tolerated the presence of bulky residues such as Phe, Trp, or Tyr at
either the P1’ or the P2’ site, provided that the other position was
occupied by Gly [21,28,29].
The aim of this study was to develop a fast and easy
methodology for cloning, expression and purification of the active
JEV NS2B(H)-NS3 serine protease and to obtain numerical data
for kinetic constants by using uorogenic model peptide substrates
for serine proteases. In addition, we also characterized inhibition
of the protease by conventional serine protease inhibitors. To the
best of our knowledge, this is the first study into the biochemical
characteristics, substrate preferences and inhibitor profile of the
protease encoded in the JEV genome.
Materials and Methods
Construction of JEV NS2B(H)-NS3pro Expression Plasmid
The full-length sequence of JEV genotype III strain JaOArS 982
NS2B-NS3 (Genebank accession number: M18370) was custom-
synthesized (Blue Heron Technology Inc., Canada) and cloned
into pLS vector (Top Gene Technologies, Canada). In close
analogy with procedures previously published for DEN NS2B(H)-
NS3pro [30], the pLS/NS2B-NS3 plasmid template was used to
PCR-amplify the NS2B(H) region (amino acids 51–95 and 121–
131 using specific primers NS2B(H)-F:
59-GGATCCGTGTCAGGAAAAGCAACAGA-
TATGTGGCTTGAACGGGC-39,
(underlined sequence represents the BamH1 restriction site) and
NS2B(H)-R 59-
GCCCCCTCTTTTTGTTGTTTTTAAAGTGAGCCAA-
TAACCTGGAA CACCGGGAT CATCAATC-39,
where the overlapping sequence is in bold; the NS3(pro) region
(amino acids 1–180) using primers
NS3(pro)-F
59-CCCGGTGTTCCAGGTTATTGGCTCACTTT-
TAAAAACAACAAAAAGA-GGGGGCGTGTTTTGGGA-
CACGC-39,
(overlapping sequence in bold letters);
and NS3(pro)-R
59-GGTACCCTATCTCTTTCTCAACATGTTTGGGGTG-
TAAGC-39
(underlined sequence represents the Kpn1 restriction site and the
sequence in italic indicates the introduced stop codon).
All oligonucleotides were purchased from Proligo Singapore Pte
Ltd.
PCR was performed by using a thermal cycler GeneAmp PCR
system Model 2400 (Perkin Elmer Cetus, USA), with pre-
denaturing (95uC, 5 minutes), 25 cycles of denaturing (95uC, 60
seconds), annealing, (50uC, 30 seconds), extension (72uC, 2
minutes), and final extension (72uC, 8 minutes).
The NS2B(H)-NS3(pro) fragments containing NS2B residues
51–95 followed by residues 121–131, and the first 180 residues of
NS3(pro) were constructed from the full-length sequence by
overlapping extension PCR. PCR products harboring overlapping
sequences, NS2B(H) and NS3(pro), were combined and subjected
to splicing by overlap extension PCR (SOE-PCR) using primer
pairs, NS2B(H)-F and NS3(pro)-R. The resulting SOE-PCR
products were separated by agarose gel electrophoresis, and the
800 bp fragment was excised and purified by QIAquickH gel
extraction kit (QIAGEN, Germany).
The purified PCR products and pTrcHisA (Invitrogen, USA)
vector were digested with restriction enzymes BamH1 and Kpn1
and purified by QIAquick purification kit. Insert DNA and
pTrcHisA vector were combined at a 16:1 molar ratio in a ligation
reaction containing 16ligation buffer (50 mM Tris-HCl, pH 7.6,
10 mM MgCl2, 1 mM ATP, 1 mM DTT, 25% (w/v) poly-
ethylene glycol 8000) and five units of T4 DNA ligase (Gibco BRL,
USA) in a final volume of 20 ml and incubated overnight at 14uC,
resulting in NS2B(H)-NS3pro carrying a N-terminal (His)6
purification tag.
The sequence of the recombinant (His)6-NS2B(H)-NS3pro
construct was confirmed by DNA sequence analysis (Macrogen
Inc., South Korea), using the sequencing primers, pTrcHis-F: 59-
GAGGTATATATTAATGTATCG-39; and pTrcHis-R: 59-
CTGAAAATCTTCTCTCATC-39.
Expression and Purification of NS2B(H)-NS3pro
Escherichia coli DH5a (GIBCO BRL, USA) was used as host cell
for plasmid propagation. E. coli C41 (F
2, ompT, hsdSB, (rB
2 mB
2),
gal, dcm, l(DE3)), derived from E. coli C41 (DE3), was used as
expression host. Constructs were transformed into E. coli (BL21)
and cells were grown in one liter LB medium containing 100 mg
ml
21 ampicillin, at 37uC, until OD600 reached 0.6. Expression was
induced by isopropyl b-D-1-thiogalactopyranoside (IPTG) at
a concentration of 0.2 mM and cells were incubated for 15 h at
18uC. Cells were harvested by centrifugation (6000 6g, 4uC, 10
minutes) and the pellet was resuspended in 30 ml lysis buffer
Japanese Encephalitis Virus NS3 Protease Kinetics
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21 lysozyme,
10 mgm l
21 DNase, and 5 mM MgCl2). Cells were kept at room
temperature for 30 minutes and then lysed on ice by sonication
using an Ultrasonic Processor XL (Misonix Inc. NY). Insoluble
material was pelleted by centrifugation (15000 6 g, 4uC, 20
minutes), and the soluble fraction was filtered through 0.22 micron
filters (Pall Corporation, USA). Histidine-tagged NS2B(H)-NS3pro
was purified by immobilized metal ion affinity chromatography
(IMAC). Nickel-sepharose HisTrap
TM HP 5 ml columns (GE
Healthcare, Sweden) were pre-equilibrated with 10 column
volumes sample buffer (0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl)
and the sample (30 ml from 1.0 liter of bacterial culture) was
loaded at a flow rate of 1 ml min
21, using an FPLC pump
(A ¨KTA
TMFPLC
TM system, GE Healthcare). The column was
washed with 10 column volumes of degased washing buffer (0.1 M
Tris-HCl, pH 7.5, 0.3 M NaCl, 30 mM imidazole). Protein was
eluted with ten column volumes elution buffer (0.1 M Tris-HCl,
pH 7.5, 0.3 M NaCl, 0.3 M imidazole) at flow rate of 1.0 ml
min
21. Elution was monitored by absorbance at 280 nm using
a UV detector (A ¨KTA
TMFPLC
TM system, GE Healthcare) and
fractions of 1.0 ml were collected. Aliquots of 20 ml from each
fraction were loaded onto a 15% SDS-PAGE gel and electropho-
resis was performed in Tris-glycine buffer (25 mM Tris-HCl,
pH 8.3, 192 mM glycine and 0.1% SDS). The gel was stained
with Coomassie-Blue staining solution (0.1% Coomassie-Brilliant-
Blue R250, 50% methanol and 10% glacial acetic acid) with
shaking at room temperature for 2 hours, and then destained with
shaking in destaining solution (10% methanol and 10% glacial
acetic acid) at room temperature, overnight. Western blotting was
performed using anti-hexahistidine antiserum (Invitrogen, CA,
USA) at 1:10,000 dilution. Fractions containing NS2B(H)-NS3pro
were desalted by step-wise dialysis at 4uC by using SPECTRA/
POR dialysis membranes (6–8 kDa MWCO) (Spectrum Medical
Industries, Inc. MA, USA), against three batches of a 100-fold
sample volume buffer A (0.1 M Tris-HCl, pH 8.5, 0.2 M NaCl),
one batch of a 200-fold volume buffer B (0.1 M Tris-HCl, pH 8.5,
0.1 M NaCl, 5% (v/v) glycerol) and one batch of a 200-fold
volume of buffer C (0.1 M Tris-HCl, pH 9.5, 5% (v/v) glycerol).
Purified NS2B(H)-NS3pro was further concentrated to 1.0 mg
ml
21 by centrifugal filter devices (Centricon 15 ml, 5 kDa
MWCO, Millipore, USA) at 4uC. Protein concentrations were
determined with a Bradford protein micro-assay using (Bio-Rad,
USA) with bovine serum albumin (Sigma Chemistry) as calibration
standard. Samples were stored in 50 mM Tris-HCl, pH 9.0, (50%
v/v) glycerol, at 220uC.
Assay of Enzymatic Activity
Enzymatic activity of purified NS2B(H)-NS3pro was assayed
against commercially available synthetic peptide substrates con-
taining either three non-prime side residues, Boc-GRR-amc and
Boc-LRR-amc; four residues, Ac-nKRR-amc, Ac-nKRR-amc;
and five residues, Pyr-RTKR-amc, and a previously described
internally quenched DEN NS3 substrate, Abz-(R)4SAGnY-amide
[22] (all purchased from Peptides International, KY, USA).
Cleavage of amc from the peptide substrates was monitored on
a microtiter plate fluorometer using a Beckman Coulter DTX 880
multimode reader (Beckman Coulter, CA, USA) at an excitation
wavelength (l)=360 nm and an emission wavelength
(l)=485 nm for all substrates, except for Abz-(R)4SAGnY-amide
(excitation wavelength (l)=320 nm and emission wavelength
(l)=420 nm). Assays were conducted on 96-well flat bottom black
polystyrene microplates (Corning Life Sciences, MA, USA) in
a reaction volume of 100 ml containing 0.5 mM NS2B(H)-NS3pro,
assay buffer (50 mM Tris-HCl, pH 9.5, 30% glycerol) and
substrate at concentrations ranging from 2.5 to 1500 mM.
Reaction mixtures were pre-incubated for 30 min at 37uC and
started by addition of the substrate. Fluorescence release was
monitored every 30 seconds over a period of 5 min and relative
fluorescence units were converted to rates of product formation by
calibration with free amc (Sigma Chemistry, St. Louis, USA).
Inner filter effects were corrected for as described in the literature
[31]. Reaction velocities at steady state were calculated from the
slope of reaction progression curves by non-linear regression of
initial velocities using Graphpad Prism software. Kinetic param-
eters, Km, kcat and catalytic efficiency kcat/Km, were calculated
assuming Michaelis-Menten kinetics, v=Vmax(S)/(S)+Km). No
significant hydrolysis of the peptide substrates was observed in
the absence of enzyme.
The effect of pH on enzymatic activity on the JEV protease was
determined by assays in different buffers in the pH range from
6.5–11.0 (50 mM MES, pH 6.5; 50 mM MOPS, pH 7.0; 50 mM
Tris-HCl, pH 7.5, 8.0, 8.5, 9.0 and 9.5, and 50 mM CAPS,
pH 10.0, 10.5 and 11.0) with 20% (v/v) glycerol in each assay
using 100 mM Ac-nKRR-amc as substrate. The effect of ionic
strength on enzyme activity was examined in assay reactions
containing 0–200 mM NaCl in 50 mM Tris-HCl, pH 9.5, 30%
(v/v) glycerol, 0.5 mM enzyme and 100 mM Pyr-RTKR-amc
substrate.
Enzyme inhibition was characterized by using aprotinin (Sigma
Chemistry, USA) as model inhibitor. JEV NS2B(H)-NS3pro
(0.5 mM) was incubated in assay buffer (50 mM Tris-HCl
pH 9.5, 20% (v/v) glycerol) in the presence of increasing
concentrations of aprotinin (0–20 mM) at 37uC for 30 minutes.
Reactions were started by adding 10 mM Pyr-RTKR-amc sub-
strate. IC50 values for aprotinin were determined from dose-
response curves. Experiments were performed in triplicate and the
standard deviation of all reported numerical values was ,10%
with exception of the Boc-LRR-amc peptide substrate where SD
was 12.5%.
Sequences Alignment and Homology Modelling
Amino acid sequences of the NS2B-NS3 of WNV, JEV, DEN2
and YFV (UniProt IDs: P06935, P27395, P2999 and Q6DV88)
were imported from the Universal Protein Resource, UniProt [32].
Multiple sequence alignment of the four NS2B-NS3 proteases was
done with ClustalW, realized in UniProt.
The crystal structures of the WNV protease/inhibitor
complex (NS2B(H)-NS3-protease-Bz-nKRR-H, PDB ID: 2FP7)
was used as template to build a model of the JEV NS2B(H)-
NS3-protease. A pairwise sequence alignment was first done for
the WNV and JEV NS2B-NS3 proteases using the ClustalW
algorithm of UniProt. Homology models were then built using
Modeller 9.9 [33]. The model with the lowest DOPE Score was
chosen as the best.
Results
3.1. Cloning, Expression and Purification of JEV NS2B(H)-
NS3pro
Starting from an in vitro synthesized gene sequence encoding
the full-length NS2B-NS3 protein from JEV, an enzymatically
active single-chain protease NS2B(H)-NS3pro was constructed
by SOE-PCR and cloned downstream of an N-terminal
hexahistidine purification tag into expression vector pTrcHisA
(Fig. 1). Recombinant plasmid DNA was transformed into E. coli
DH5a followed by rapid size screening and restriction digestion
analysis. The complete sequence of the cloned JEV NS2B(H)-
NS3pro was analyzed by automated DNA sequencing in both
Japanese Encephalitis Virus NS3 Protease Kinetics
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compared to the nucleotide sequence of JEV genotype III strain
JaOArS 982 [Genebank accession number M18370.1]. No
premature stop codons or amino acid substitutions were
introduced in the recombinant sequence. NS2B(H)-NS3pro
was expressed upon incubation for 12 h in the presence of
0.2 mM IPTG, predominantly as a soluble protein and was
purified to .95% purity by a single-step chromatography on
Ni
2+ - metal chelate affinity columns, eluting at 0.3 M imidazole
(Fig. 2). SDS-PAGE analysis and subsequent Western immuno-
blotting with anti-polyhistidine antibodies of the purified protein
revealed the presence of two major proteins with molecular
weights 21 and 10 kDa, and a relatively faint band at 36 kDa,
thereby suggesting almost complete autocleavage of the enzy-
matically active NS2B(H)-NS3pro protease at the native NS2B/
NS3 cleavage site (Fig. 3).
3.2 Enzyme Assay with Fluorogenic Peptide Substrates
Enzymatic activity of the recombinant NS2B(H)-NS3pro pro-
tein was assayed by fluorescence release from several small
synthetic peptide substrates resembling the dibasic cleavage site
sequences of the JEV polyprotein precursor. In addition, we have
analysed the activity of JEV NS2B(H)-NS3pro by using a tetrabasic
internally quenched fluorescent peptide, Abz-(R)4SAGnY-amide,
originally described for the DEN NS3 serine protease [22].
Peptide substrates labelled with the amc reporter group comprised
three to five amino acid residues at the non-prime side, whereas
the tetrabasic substrate contained three residues added to the
Figure 1. Schematic representation of primer binding sites and physical map of pTrcHisA/NS2B(H)-NS3(pro). (A) The figure illustrates
the NS2B(H)-NS3(pro) fragment and the primer binding positions. The NS2B(H), NS2B C terminal 11 amino acid residues linker and NS3 protease
domains are shown. The NS2B-NS3 cleavage site is represented as a triangle. PCR primers are shown in maroon lines representing overlapping
sequences. Amino acid positions within NS2B and NS3 are shown as black letters. (B) Shown is the recombinant plasmid, pTrcHisA/NS2B(H)-NS3(pro)
of JEV encoding the 31 kDa NS2B(H)-NS3(pro) from JEV. The plasmid backbone contains the trc promoter (pTrc), lac operator (lacO), polyhistidine
(His)6 tag, Xpress
TM epitope (Xpress), ampicillin resistance gene (AmpR) and lacI
q repressor genes (lacIq). The plasmid map was generated by the
Vector NTI program.
doi:10.1371/journal.pone.0036872.g001
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each substrate (RFU min
21) were converted to concentrations of
released amc and velocities (nm min
21) were re-plotted as
a function of substrate concentration (Fig. 4). Upon correction of
inner filter effects, data were in excellent agreement with
Michaelis-Menten kinetics, as revealed by non-linear least square
fit of data, and kinetic parameters, Km, kcat, and catalytic efficiency
kcat/Km, were determined for each substrate (Table 1).
Sequences of the peptides analysed showed differing substrate
binding activities (Km) as well as substrate turnover (kcat) and kinetic
data obtained for the substrates displayed relatively large
variations ranging from kcat/Km 3.74 M
21 s
21 (Boc-LRR-amc)
to 1,963 M
21 s
21 (Pyr-RTKR-amc). The most inefficient sub-
strate (based on kcat/Km) was Boc-LRR-amc, with a low kcat of
0,00015 s
21. Although the second least efficiently cleaved amc-
labeled substrate, Boc-GRR-amc, showed a 3-fold higher Km
(123 mM), turnover was approximately 10-fold greater than for
Boc-LRR-amc. In earlier studies Boc-GRR-amc has shown Km of
142 mM and kcat of 0.034 s
21 on NS2B/NS3 protease of YFV and
Km of 150 mM and kcat of 0.13 s
21 on NS2B/NS3 protease of
DEN2 [34,35] Thus, this substrate containing P2-P1 Arg-Arg as in
cleavage sites of YFV and DEN2 viruses seem to be bound equally
tight, but cleaved with lower turnover by JEV protease than by
YFV and DEN2 proteases.
The most efficiently cleaved substrate, Pyr-RTKR-amc, had the
lowest Km (9 mM) and the highest turnover number (0.0176 s
21)o f
all amc-labelled peptides. This substrate has been described in an
earlier study on DEN2 NS2B-NS3 protease where values of
134 mM, 0.013 s
21 and 97 M
21 s
21 were reported for Km, kcat
and kcat/Km respectively [24]. It was also described in another
study on N2B-NS3 proteases of WNV and DEN2, where the Km,
kcat, and kcat/Km values were 71 mM, 6.3 s
21 and 88000 M
21 s
21
for WNV protease and 3.6 mM, 0.02 s
21 and 5500 M
21 s
21 for
DEN2 [29]. Data obtained for kcat/Km with the substrate peptides
Ac-nKRR-amc and Bz-nKRR-amc revealed a discernible contri-
bution of the N-terminal protection group on the activity of the
respective substrate, whereby the benzoyl moiety contributes to an
approximately 1.4-fold higher kcat/Km when compared to the
acetyl group.
Although the internally quenched substrate Abz-(R)4SAGnY-
amide was shown previously to be efficiently cleaved by DEN
NS2B(H)-NS3pro, (kcat/Km: 11087 M
21 s
21) [22], binding affinity
and cleavage efficiency (kcat/Km:1 9M
21 s
21) of this peptide was
substantially lower (approx. 580-fold) for JEV NS2B(H)-NS3
protease than for the DEN NS3 protease. This finding is in
agreement with notable differences in substrate preferences
between JEV and DEN NS3 as assumed from a comparison of
cleavage site sequences present in the viral polyprotein precursor
[29].
The effect of pH on the enzymatic activity of JEV protease was
determined by assays using buffers in the pH range from 6.5–11.0
(Fig. 5, panel A). In agreement with earlier reports on flaviviral
proteases [15,24,25,36] the pH optimum for reaction with the
peptide substrate Ac-nKRR-amc was 9.5. It is noteworthy that the
activity of the enzyme at physiological pH is less than 25% of the
activity observed at pH 9.5.
Flaviviral serine proteases exhibit marked inhibition by high salt
concentrations [24,25], and we examined effects of elevated ionic
strength by high concentrations of NaCl (Fig. 5, panel B).
Cleavage of the substrate Pyr-RTKR-amc was inhibited by about
50% in the presence of 25 mM NaCl, which can be compared to
the 40–50% inhibition of the dengue virus NS3 protease caused by
100 mM NaCl, as earlier reported [24,37], thereby suggesting an
even greater sensitivity of the JEV NS3 and MVEV proteases to
high ionic strength.
Figure 2. Purification profile of JEV NS2B(H)-NS3(pro) by Ni
2+
affinity column. This figure shows a chromatogram from the
purification of JEV NS2B(H)-NS3(pro) by Ni
2+ affinity chromatography
The column was washed with 0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 30 mM
imidazole (peak A) and NS2B(H)-NS3pro was eluted with elution buffer
(0.1 M Tris-HCl, pH 7.5, 0.3 M NaCl, 0.3 M imidazole (peak B).
doi:10.1371/journal.pone.0036872.g002
Figure 3. SDS-PAGE and Western blot analysis of NS2B(H)-
NS3(pro). (A) Samples from the IMAC column were loaded onto a 15%
SDS-PAGE gel and electrophoresis was performed in Tris-glycine buffer.
The gel was stained with Coomassie-Blue. Lane M, broad range protein
marker; lane 2, IMAC flow-through; lane 3, 30 mM imidazole wash peak;
lane M imidazole elution peak. (B) Western blot profile using N-terminal
anti-His antibody on 15% SDS-PAGE. Lane 1, 30 mM imidazole peak
fraction; lane 2, 0.3 M imidazole peak fraction; lane 3, 0.3 M imidazole
after dialysis (desalting); lane 4, 0.3 M imidazole peak fraction after
dialysis and concentrating (Centricon, Millipore). The band representing
the intact protein shows the highest intensity upon induction of
expression.
doi:10.1371/journal.pone.0036872.g003
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proteases from DEN and WNV are comparatively insensitive to
inhibition by conventional protease inhibitors, like PMSF and
benzamidine [25,47]. We here evaluated the inhibitory activities of
aprotinin on the JEV protease. Dose-response plots in the presence
of increasing inhibitor concentrations assayed with the Pyr-
RTKR-amc substrate suggest IC50 values of 4.1360.17 mM for
aprotinin (Fig. 6). Previous studies have reported Ki values for
aprotinin of 0.162 mM for WNV NS3 protease, and 0.026 mM for
DEN2 NS3 protease [15]. Similarly, for MVEV NS2B-NS3, the
IC50 of aprotinin is about 8 mM [14]. In another study, using
a non-cleavable form of WNV NS2B-NS3pro, the Ki of aprotinin
was reported as 26 nM [38].
Thus, in comparison, JEV NS3 protease appears to be even less
susceptible to this protease inhibitor evaluated here.
3.3 Structural Comparisons of JEV Protease with WNV,
DEN and YVF Proteases
The alignment of the JEV, WNV DEN2 and YFV polyprotein
sites cleaved by NS2-NS3 proteases is shown in Fig. 7. As seen, the
JEV and WNV sites are the most similar; they all contain Lys-Arg
at the P2-P1 positions, while at the P’1 position a Gly is present at
Figure 4. JEV NS2B(H)-NS3(pro) catalysed substrate hydrolysis rates at different substrate concentrations. The graph shows reaction
velocities of JEV NS2B(H)-NS3(pro) for hydrolysis of Boc-GRR-amc (A); Boc-LRR-amc (B); Ac-nKRR-amc (C), Bz-nKRR-amc (D), Pyr-RTKR-amc (E), and Abz-
(R)4SAGnY-amide (F). Assays were performed at 37uC in 50 mM Tris-HCl, pH 9.5, 30% v/v glycerol. Kinetic parameters were determined by non-linear
fitting of untransformed data to the Michaelis-Menten equation. Data are reported as the mean of three experiments 6 standard error (SEM).
doi:10.1371/journal.pone.0036872.g004
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which contains a Ser). The DEN2 and YFV sites are less similar
with those of JEV, however; in six cases out of ten, these sites have
Arg-Arg at the P2-P1 positions, while the four remaining sites have
different positively charged residues (Lys-Arg, Arg-Ser, Gln-Arg
and Arg-Lys) at these positions. It is also notable that the five
cleavage sites of JEV contain five different amino acids at P3; the
same holds true for P4.
The multiple sequence alignment of the WNV, JEV, DEN2 and
YFV NS2B-NS3 proteases is shown in Fig. 8. The alignment
revealed that the JEV protease is closest to WNV, with a sequence
identity of 76.3% (93.7% sequence similarity), while the DEN2
and YFV proteases show only 50.2% and 45.5% sequence identity
(79.5% and 76.9% sequence similarity) with the JEV protease,
respectively.
The X-ray crystal structure of the WNV protease/inhibitor
complex NS2B(H)-NS3-protease-Bz-nKRR-H [27] indicates that
the WNV NS2B-NS3 protease has four distinct substrate binding
pockets, termed S4-S1, which accommodate the P4-P1 residues of
protease substrates [39]. The S1 pocket is composed of nine
residues; the key interactions with P1 Arg are being formed by the
side chain of Asp129 and the backbone carbonyl oxygen of the
Tyr130 residue of NS3. A large part of the S1 pocket comprises
the aromatic side chains of Tyr150 and Tyr161 of NS3. In the X-
ray structure Tyr161 is forming a cation-p stacking with P1
arginine, which is located between Tyr161 and Bz cap of the
inhibitor; possible cation-p stacking of substrate P1 arginine with
Tyr150 is also suggested from mutagenesis studies [40,48]. The S2
pocket of the WNV protease is outlined by eight residues and is
dominated by a negative electrostatic potential from backbone
carbonyl oxygen atoms of Asp82 and Gly83 of NS2B, and Val71
and Lys72 of NS3, as well as from acidic side chains of Asp82 of
NS2B and Asp75 of the catalytic triad. S3 and S4 pockets are less
well defined and consist of a few (three and two, respectively)
uncharged amino acids, which makes the substrate P4 and P3
residues being largely solvent exposed. The sequence stretches
contributing to the S4-S1 pockets are marked in the multiple
alignment of Fig. 8. As seen, JEV and WNV share the same amino
acid at 17 of the 22 indicated positions; JEV and DEN2 share the
same amino acid at 11 positions and JEV, and YFV at 12
positions. However, there are positions in each one of S4-S1
pockets, which contain physico-chemically quite different amino
acids. Residue 84 of NS2B contributes to the S2 pocket, and is
Asp, Asn, Ser and Glu in, respectively, JEV, WNV, DEN2 and
YFV. Residue 86 of NS2B is part of the S3 pocket and contains
also four different amino acids in the four viruses (His, Gln, Ser,
Table 1. JEV NS2B(H)-NS3 Kinetic Parameters for Fluorogenic
Substrates.
Substrate Km(mM) kcat(s
21) kcat/Km(M
21s
21)
Boc-GRR-amc 123611.6 0.003760.0002 30.0862.7
Boc-LRR-amc 4065.0 0.0001560.0001 3.7460.3
Ac-nKRR-amc 3262.5 0.0117860.00054 368.13617.0
Bz-nKRR-amc 2061.34 0.0160.00023 500.00611.3
Pyr-RTKR-amc 9.060.82 0.017660.0008 1962.96685.0
Abz-(R)4SAGnY-amide 20.9162.04 0.0004060.000014 19.00061.85
doi:10.1371/journal.pone.0036872.t001
Figure 5. Effect of pH and ionic strength on the proteolytic activity of NS2B(H)-NS3(pro) from JEV. (A) Shown are activities as assayed by
using 150 mM Ac-nKRR-amc substrate at 37uC at pH ranging from 6.5–11.0 by using different buffers (50 mM MES, MOPS, Tris, CAPS). (B) Ionic
strength dependence of JEV NS2B(H)–NS3(pro) enzyme activity. Assay was performed at 37uC using 100 mM Pyr-RTKR-amc, 0.5 mM enzyme and
50 mM Tris-HCl pH 9.5 buffer containing 20% glycerol (v/v) in the presence of increasing salt concentrations (0–200 mM).
doi:10.1371/journal.pone.0036872.g005
Figure 6. JEV NS2B(H)-NS3 Inhibition Dose-Response Curve.
Inhibition of NS2B(H)-NS3 protease activity mediated by aprotinin. The
inhibition was performed by incubation of 0.5 mM of NS2B(H)-NS3 in
assay buffer (50 mM Tris-HCl, pH 9.5, 20% glycerol) with increasing
concentrations of aprotinin (0.0–20 mM). The results are representative
of three independent experiments.
doi:10.1371/journal.pone.0036872.g006
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S4 pockets, respectively, are also different in the different
proteases. These amino acid differences are thus likely candidates
to contributing to the differences in kinetics of substrates for the
different proteases.
In order to cast further light into this possibility, we built
a homology model of the JEV NS2B-NS3 protease, using the
crystal structure of a WNV NS2B(H)-NS3-protease-Bz-nKRR-H
inhibitor complex as template. The model for the JEV protease is
shown superimposed on the WNV protease/inhibitor complex in
Fig. 9, panel A. Pairwise 3D structure alignment showed that the
JEV and WNV proteases share large structural similarity
(RMSD=0.172 A ˚), with a large structural conservation in the
enzymes’ active sites. However, clear differences are seen in the
substrate-binding pockets at NS2B residues Asn84, Gln86, and
NS3 residues Thr132, Ile155 (WNV NS2B-NS3 protease num-
bering, corresponding to NS2B residues Asp84, His86, and NS3
residues Arg132, Glu155 in the JEV protease). This is visualized in
Fig. 9, panels B and C. Side chains of all four residues are in close
proximity with the ligand and are capable of forming multiple
hydrogen bonds (except Ile 155 in the WNV protease). The
superimposition shows that the change of these residues between
JEV and WNV leads to a serious rearrangement of the H-bond
network in the substrate-binding pocket, which very likely will
affect the cleavage preferences of the two proteases. Moreover,
while all these residues are uncharged in the S1-S4 pockets of the
WNV protease, the corresponding residues in the S2 and S4
pockets of the JEV protease are acidic (Asp and Glu) while in the
S1 pocket it is basic (Arg). All of this may influence both the ionic
interactions with substrates and the geometries of the binding
pockets.
Discussion
Over the past decade, the NS2B-NS3 two-component serine
proteases of human-pathogenic flaviviruses have received sub-
stantial scientific interest as potential drug targets, as these
enzymes are indispensable components of virus replication
[13,19,41]. Compared to the NS3 proteases of the closely related
DEN and WNV, the NS3 protein from JEV is much less well
characterized. In this study we report a straightforward procedure
for producing recombinant JEV NS2B(H)-NS3pro protease by
overexpression in E. coli followed by an one-step purification
procedure, and we report the kinetic parameters of the protease
for commercially available synthetic fluorogenic model peptide
substrates and serine protease inhibitors.
The full-length NS2B-NS3 polyprotein region of JEV was
obtained by time- and cost-efficient gene synthesis, and was used
Figure 7. Multiple sequence alignment of WNV, JEV, DEN and YFV cleavage junctions recognized by the NS2B-NS3 protease. The
arrow above the sequences shows the scissile bond cleaved by the protease. The sequences which served as basis for the fluorogenic substrates used
herein are marked with colors (Abz-(R)4SAGnY-amide (yellow), Ac-nKRR-amc and Bz-nKRR-amc (green), Pyr-RTKR-amc (blue), and Boc-GRR-amc
(purple). The conserved amino acids Lys-Arg at the P2-P1 positions in JEV and WNV are marked in bold font.
doi:10.1371/journal.pone.0036872.g007
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complex comprising residues 51–95 and residues 121–131 from
the NS2B cofactor and N-terminal residues 1–180 of the NS3
protease domain. Previous studies have demonstrated that such
a construct is catalytically active both in proteolytic autocleavage
conducive to the formation of a non-covalent NS2B(H)-NS3pro
complex and with peptide substrates supplied for in trans cleavage
reactions [24].
The recombinant NS2B(H)-NS3pro protein produced by E. coli
was predominantly biosynthesized as a soluble protein, and could
be easily purified by metal chelate affinity chromatography to
.95% purity. In SDS-PAGE analysis, the purified protein
displayed bands of 36, 21 and 10 kDa, corresponding to the
NS2B(H)-NS3pro precursor, the NS3pro protease domain and the
histidine-tagged NS2B(H) cofactor, respectively. Similar to the
protein from DEN, the 29.8 kDa (His)6NS2B(H)-NS3pro protein
of JEV exhibits anomalous migration in SDS-PAGE gels. In
contrast to the corresponding protein from DEN serotype 2, the
NS2B(H)-NS3pro protein from JEV was largely soluble upon
expression in E. coli, thus suggesting the existence of major
conformational differences between the two proteins.
In analogy to a number of specificity studies on the NS3
proteases from DEN and WNV [15,29,42,43], we assayed a small
set of commercially available fluorogenic peptide substrates, based
on P3-P1 sequences of cleavage sites (capsid protein, NS2B/NS3
itself, NS3/NS4A, and NS4B/NS5 cleavage site) of NS2B/NS3
proteases of WNV, YFV, and JEV. In addition, we assayed an
internally quenched peptide, Abz-(R)4SAGnY-amide, represent-
ing the P4-P3’ sequence of the capsid protein cleavage site of the
DEN-2 virus [22].
Among all substrates used, the highest binding affinity and
cleavage efficiency was observed for the Pyr-RTKR-amc sub-
strate, which represents the native JEV NS2B/NS3 cleavage site at
the P3 to P1 positions. The binding affinity for the substrate with
a leucine at P3 (Boc-LRR-amc) was three-fold higher when
compared to that with a glycine at P3 (Boc-GRR-amc); however,
the catalytic efficiency for Boc-GRR-amc was about 10-fold higher
than for Boc-LRR-amc, thereby suggesting a significant contribu-
tion of this position to the catalytic mechanism as seen in an earlier
report for the DEN NS3 protease [44]. The LRR-amc substrate
also displays the lowest catalytic efficiency of all tested peptides.
Boc-GRR-amc and Boc-LRR-amc were previously assayed with
the NS3 proteases from DEN and WNV, where it was found that
both enzymes prefer a Gly residue to a Leu at the P3 position
[15,44]. Our results indicate that hydrolysis of substrates with
a short chain amino acid (Gly) at the P3 position is favoured by the
JEV NS2B(H)-NS3 protease over those with a bulky residue (Leu),
which aligns with previous data reported for the DEN2 and WNV
proteases [15,45]. The prominent contribution to catalytic
efficiency of residues at the P3 and P4 position (and possibly
Figure 8. Multiple sequence alignment of the NS2B-NS3 protease of WNV, JEV, DEN and YFV. Residues located in the S1, S2, S3 and S4
pockets are marked in colours cyan, yellow, green and magenta, respectively (data from [39]). Non-conserved residues located at the binding pockets
are marked by bold italic font.
doi:10.1371/journal.pone.0036872.g008
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comparatively weak activity of the internally quenched peptide
Abz-(R)4SAGnY-amide, which is an efficient NS3 substrate
originally designed from the capsid protein sequence
RRRR.SAG of DEN2 [22]; here it demonstrated a 580-fold
lower kcat/Km when assayed with the JEV enzyme, compared with
DEN2. Whereas the tetrabasic non-prime side sequence is strongly
favoured by DEN NS3, the presence of Asn and Gln at P3 and P4
of JEV apparently confers a high difference in specificity between
the two enzymes. Moreover, it can not be ruled out that the prime-
side sequences (SAG in DEN and GGN in JEV) contribute
substantially to the decrease in efficiency as seen for this substrate
peptide.
Although kinetic data for the JEV protease are relatively limited
to date, it can be concluded that the enzyme from JEV favours
substrates with Lys-Arg at the P2-P1 position, while the NS3
proteases from DEN and YFV prefer Arg-Arg at this position; data
which thus suggest a greater similarity of the JEV protease to
WNV than to DEN [15]. This view is supported by amino acid
sequence alignments, the crystal structures for the enzymes from
DEN and WNV, and structure-guided mutagenesis studies, which
show that functional determinants of activation and substrate
recognition for JEV and WNV are more closely related than other
flaviviral proteases (Fig. 7). It is noteworthy that both the whole
sequence and the substrate binding regions of the NS2B-NS3
protease JEV show much higher identity to WNV than to DEN2
and YFV proteases (Fig. 8 and [46]).
We carried out multiple sequence alignment of the NS2B-NS3
proteases of WNV, JEV, DEN and YFV, which allowed
identifying differences in the putative binding pockets of the
proteases (Fig. 8). We identified four amino acid residues (positions
84 and 86 in NS2B and 132 and 155 in NS3), which were different
for all four proteases. In order to confirm the role of these residues
in substrates binding and cleavage preferences of NS2B-NS3
proteases, we built a 3D homology model of the JEV NS2B-NS3
protease and compared its substrate binding pocket with that of
the WNV NS2B-NS3 protease (Fig. 9). The structural modeling
revealed that the conformation of the JEV protease is overall
highly similar with the structure of the WNV NS2B-NS3 complex
[21,27,45]. However, it can be seen that the change of Asn84,
Gln86, Thr132 and Ile155 in WNV NS2B-NS3 protease to
Asp84, His86, Arg132 and Glu155 in the JEV NS2B-NS3
protease leads to rearrangement of the possible H-bonds between
the ligand and the S1, S3, and S4 pockets of the enzyme (Fig. 9,
panel B, C). Moreover, presence of an acidic amino acid in S4 and
a basic amino acid in S1 may influence both the binding pocket
geometry and ligand-protease interactions. This makes the
proteases of the two viruses quite different in terms of their
binding mode, affinity and cleavage preferences and are likely
reasons for the observed differences in the cleavage efficiency of
substrates for the JEV and WNV enzymes.
An earlier study employing hybrid NS2B-NS3 constructs of
DEN and JEV sequences showed that only a (DEN)NS2B-
(JEV)NS3 protein could efficiently process the JEV polyprotein,
whereas the (JEV)NS2B-(DEN(NS3) construct was inactive,
supporting the notion that NS2B proteins of different origins
modulate the structure and substrate affinity of the protease
[21,28]. This also indicates that there are likely differences in the
Figure 9. Structures of JEV and WNV proteases bound to Bz-nKRR-H. (A) Superimposition of the WNV X-ray structure (PDB ID 2FP7) on the
JEV homology model. The WNV structure is shown in blue (NS2B) and cyan (NS3); the JEV structure in orange (NS2B) and green (NS3). The Bz-nKRR-H
inhibitor in the WNV structure is shown in stick representation in yellow. (B) Detailed interactions of Bz-nKRR-H with WNV (from X-ray structure). (C)
Superimposition of the Bz-nKRR-H X-ray structure (PDB ID 2FP7) on the JEV homology model. Potential hydrogen bonds indicated by dashed lines.
Putative interacting amino acid residues of WNV and JEV are represented in cyan and green, respectively, and Bz-nKRR-H in yellow.
doi:10.1371/journal.pone.0036872.g009
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different flaviviruses.
The protein inhibitor aprotinin was found to inhibit JEV
NS2B/NS3 protease with surprisingly low potency (IC50:
4.1360.167 mM); this inhibitory efficiency is comparable with
the previously reported inhibitory efficiency of aprotinin for the
MVEV NS3 protease (IC50: 7.862.9 mM) [14]. It is noteworthy
that there are several reports where differences in the susceptibility
of the WNV protease to aprotinin was seen [48,49], possibly
suggesting a modulation of inhibitor sensitivity by recombinant
sequences introduced by genetic engineering.
To sum up, in this study we present for the first time
a comparative enzyme-kinetic analysis of a recombinant JEV
protease by employing model substrate peptides. Our data
demonstrate that the JEV protease shows marked differences to
other known flaviviral proteases. Our study may serve as an entry
point to the development of efficient JEV inhibitors, e.g. by
employment of high-throughput screening.
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